Generated: April 24, 2017
|Title:||Dry mix formulation for bisphosphonic acids|
|Abstract:||Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.|
|Inventor(s):||Bechard; Simon R. (Quebec, CA), Kramer; Kenneth A. (Green Lane, PA), Katdare; Ashok V. (Norristown, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
|Filing Date:||Oct 17, 2000|
|Claims:||1. A pharmaceutical tablet comprising 6.55 mg alendronate monosodium trihydrate, 110.45 mg anhydrous lactose, 80.0 mg microcrystalline cellulose, 1.00 mg magnesium stearate, and 2.00 mg croscarmellose sodium.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.